Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.1182/blood-2023-172590
dc.identifier.other
WOS:001159306702167
dc.description.volume
dc.description.issue
Publisher
ELSEVIER
DOI
10.1182/blood-2023-172590
Abstract
65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 09-12, 2023